The Gastrointestinal Research Group
Associate Professor, Department of MedicineLiver Unit, Division of Gastroenterology, Department of Medicine Gastrointestinal Research Group
MSc (Epid), University of Calgary 2005
FRCPC, Internal Medicine (1998), Gastroenterology (1999), Hepatology (2001)
MD, University of Saskatchewan, 1994
BSc (Biology), University of Saskatchewan, 1990
My research is entirely clinical and focuses on new treatments for viral hepatitis, cholestatic/autoimmune liver disease and hepatocellular cancer. I also have interests in post-transplant care of liver transplant patients and quality of life issues (fatigue and pruritus) in chronic liver disease.
Burak KW, Le T, Swain MG. Increased sensitivity to the locomotor activating effects of corticotropin releasing hormone (CRH) in cholestatic rats: implications for cholestasis associated fatigue. Gastroenterology 2002; 122: 681-688.
Burak KW, Kremers WK, Batts KP, Wiesner RH, Rosen CB, Razonable RR, Paya CV, Charlton MR. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8: 362-369.
Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004; 99: 523-6.
Theal JT, Toosi MN, Girlan L, Heslegrave RJ, Huet PM, Burak KW, Swain M, Tomlinson GA, Heathcote EJ. A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. Hepatology 2005; 41:1305-1312.
Babatin M, Schindel L, Burak KW. Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy. Can J Gastroenterol 2005; 19: 359-365.
Does the MELD score predict mortality before and after liver transplantation at the University of Alberta? (MSC Thesis). Available online at: https://dspace.ucalgary.ca/handle/1880/44826